More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$14.61B
EPS
0.9
P/E ratio
10.6
Price to sales
1.79
Dividend yield
--
Beta
0.747344
Previous close
$88.65
Today's open
$88.05
Day's range
$86.03 - $88.85
52 week range
$62.38 - $94.16
show more
CEO
Bryan C. Hanson
Employees
20000
Headquarters
Eagan, MN
Exchange
New York Stock Exchange
Shares outstanding
169739335
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Solventum (SOLV) Boasts Earnings & Price Momentum: Should You Buy?
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Zacks Investment Research • an hour ago

Solventum (SOLV) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research • Nov 12, 2026

Solventum Q3 Earnings Call Highlights
Solventum NYSE: SOLV raised its 2026 earnings outlook after reporting third-quarter results that exceeded its expectations for organic growth and earnings, even as the reversal of advance orders weighed on sales.
MarketBeat • Nov 8, 2026

SOLV Q3 Earnings Beat Estimates Despite ERP-Related Revenues Decline
Solventum beats Q3 earnings estimates despite an ERP-driven revenue decline, raises its 2026 EPS outlook and advances its portfolio transformation.
Zacks Investment Research • Nov 6, 2026

Solventum Corporation (SOLV) Q3 2026 Earnings Call Transcript
Solventum Corporation (SOLV) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 6, 2026

Solventum Reports Third Quarter 2026 Financial Results
Reported sales decreased 7.0%; organic sales decreased 2.8%, reflecting the expected 630 basis point (bps) impact of prior quarter advance orders placed ahead of the planned ERP system cutover during the current quarter Expects full-year organic sales growth toward the high end of +2.5% to +3.0% range Increases full-year adjusted EPS guidance to $7.20 to $7.30 EAGAN, Minn., Nov. 5, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the third quarter ended September 30, 2026.
PRNewsWire • Nov 5, 2026

Solventum (SOLV) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Solventum (SOLV) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research • Nov 6, 2026

Solventum (SOLV) Tops Q3 Earnings Estimates
Solventum (SOLV) came out with quarterly earnings of $1.45 per share, beating the Zacks Consensus Estimate of $1.35 per share. This compares to earnings of $1.5 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Here's Why You Should Hold Solventum Stock in Your Portfolio for Now
SOLV's strong Q2 performance, growth investments and cost-saving program support its outlook, though higher raw material costs remain a concern.
Zacks Investment Research • Nov 5, 2026

Gear Up for Solventum (SOLV) Q3 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Solventum (SOLV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.
Zacks Investment Research • Nov 4, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Solventum Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.